-transparent.png){kind=logo}
Cyproterone acetate was given to patients with stages C and D prostatic cancer and its effect on endocrine parameters was studied. At a daily oral dose of 100 mg. cyproterone acetate induced marked reduction in the size and consistency of tumor, while it caused moderate suppression of serum luteinizing hormone, follicle-stimulating hormone and testosterone levels. Elevation of serum prolactin levels was observed after treatment with cyproterone acetate but was to a lesser degree than that caused by estrogens.
Related Publications
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1988,
Wiener klinische Wochenschrift,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
March 1988,
European journal of cancer & clinical oncology,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
April 1985,
Zeitschrift fur Urologie und Nephrologie,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1987,
Progress in clinical and biological research,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1989,
Progress in clinical and biological research,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
September 1993,
Annals of oncology : official journal of the European Society for Medical Oncology,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
June 1989,
BMJ (Clinical research ed.),
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1981,
The Prostate,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1978,
Scandinavian journal of urology and nephrology,
K Isurugi, and
K Fukutani, and
H Ishida, and
Y Hosoi
January 1981,
Urological research,
